Astrid McKeown
About
Astrid McKeown is a scholar working on Hematology, Molecular Biology and Genetics.
According to data from OpenAlex, Astrid McKeown has authored 34 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Hematology, 13 papers in Molecular Biology and 12 papers in Genetics. Recurrent topics in Astrid McKeown's work include Multiple Myeloma Research and Treatments (13 papers), Chronic Lymphocytic Leukemia Research (11 papers) and Lung Cancer Treatments and Mutations (8 papers). Astrid McKeown is often cited by papers focused on Multiple Myeloma Research and Treatments (13 papers), Chronic Lymphocytic Leukemia Research (11 papers) and Lung Cancer Treatments and Mutations (8 papers). Astrid McKeown collaborates with scholars based in United Kingdom, United States and Poland. Astrid McKeown's co-authors include Yuri Rukazenkov, Suresh S. Ramalingam, Rachel Hodge, Byoung Chul Cho, Isamu Okamoto, Thanyanan Reungwetwattana, Natasha B. Leighl, Naoyuki Nogami, Sabine Bohnet and Johan Vansteenkiste and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.
In The Last Decade
Astrid McKeown
34 papers receiving 1.2k citations
Hit Papers
Peers
Astrid McKeown
Motoshige Kudo Japan
Claus G. Haase Germany
Anna Arnal Estape United States
Sunil Mukhopadhyay United States
Ross Waite United States
Sean T. Glenn United States
Cheri Geist United States
Sanaa Nabha United States
Kelli B. Pointer United States
Elena Martínez‐Sáez Spain
Citations per year, relative to Astrid McKeown Astrid McKeown (= 1×)
peers
Motoshige Kudo
Countries citing papers authored by Astrid McKeown
Since
Specialization
Citations
This map shows the geographic impact of Astrid McKeown's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Astrid McKeown with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Astrid McKeown more than expected).
Fields of papers citing papers by Astrid McKeown
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Astrid McKeown. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Astrid McKeown. The network helps show where Astrid McKeown may publish in the future.
Co-authorship network of co-authors of Astrid McKeown
This figure shows the co-authorship network connecting the top 25 collaborators of Astrid McKeown. A scholar is included among the top collaborators of Astrid McKeown based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Astrid McKeown. Astrid McKeown is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Mateos, María‐Victoria, Paweł Robak, Marek Hus, et al.. (2025). DREAMM-7 study of belantamab mafodotin plus bortezomib and dexamethasone (BVd) vs daratumumab plus bortezomib and dexamethasone (DVd) in relapsed/refractory multiple myeloma (RRMM): A subgroup analysis in patients (pts) with high-risk cytogenetic (HRC) features.. Journal of Clinical Oncology. 43(16_suppl). 7546–7546.
2.
Hungria, Vânia, Paweł Robak, Marek Hus, et al.. (2024). Patient-Reported Outcomes From the DREAMM-7 Randomized Phase 3 Study Comparing Belantamab Mafodotin (Belamaf), Bortezomib, and Dexamethasone vs Daratumumab, Bortezomib, and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma. Clinical Lymphoma Myeloma & Leukemia. 24. S242–S242.
3.
Hungria, Vânia, Paweł Robak, Marek Hus, et al.. (2024). Patient-reported outcomes (PROs) from the DREAMM-7 randomized phase 3 study comparing belantamab mafodotin, bortezomib, and dexamethasone (BVd) vs daratumumab, bortezomib, and dexamethasone (DVd) in patients with relapsed/refractory multiple myeloma (RRMM).. Journal of Clinical Oncology. 42(16_suppl). 7543–7543.
4.
Robak, Paweł, Marek Hus, Chengcheng Fu, et al.. (2024). MM-557 DREAMM-7 Update: Subgroup Analyses From a Phase 3 Trial of Belantamab Mafodotin (Belamaf) + Bortezomib and Dexamethasone (BVd) vs Daratumumab, Bortezomib, and Dexamethasone (DVd) in Relapsed/Refractory Multiple Myeloma (RRMM). Clinical Lymphoma Myeloma & Leukemia. 24. S571–S571.
5.
Hungria, Vânia, Marek Hus, Paweł Robak, et al.. (2024). Efficacy Outcomes By Minimal Residual Disease (MRD) Negativity in Patients with Relapsed or Refractory Multiple Myeloma Treated with Belantamab Mafodotin Plus Bortezomib and Dexamethasone Vs Daratumumab, Bortezomib, and Dexamethasone: Analysis from the Dreamm-7 Trial. Blood. 144(Supplement 1). 3359–3359.
6.
Mateos, María‐Victoria, Paweł Robak, Marek Hus, et al.. (2024). DREAMM-7 update: Subgroup analyses from a phase 3 trial of belantamab mafodotin (belamaf) + bortezomib and dexamethasone (BVd) vs daratumumab, bortezomib, and dexamethasone (DVd) in relapsed/refractory multiple myeloma (RRMM).. Journal of Clinical Oncology. 42(16_suppl). 7503–7503.
7.
Mateos, María‐Victoria, Paweł Robak, Marek Hus, et al.. (2024). Results from the randomized phase III DREAMM-7 study of belantamab mafodotin (belamaf) + bortezomib, and dexamethasone (BVd) vs daratumumab, bortezomib, and dexamethasone (DVd) in relapsed/refractory multiple myeloma (RRMM).. Journal of Clinical Oncology. 42(36_suppl). 439572–439572.
8.
Dimopoulos, Meletios Α., Vânia Hungria, Atanas Radinoff, et al.. (2023). S199: A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY EVALUATING THE EFFICACY AND SAFETY OF SINGLE AGENT BELANTAMAB MAFODOTIN VS POMALIDOMIDE PLUS DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (DREAMM-3). HemaSphere. 7(S3). e072005a–e072005a.
9.
Hungria, Vânia, Katja Weisel, Brooke M. Currie, et al.. (2023). P964: PATIENT (PT)-REPORTED OUTCOMES IN PTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) TREATED WITH BELANTAMAB MAFODOTIN (BELAMAF) VS POMALIDOMIDE/LOW DOSE DEXAMETHASONE (PD) IN THE DREAMM-3 STUDY. HemaSphere. 7(S3). e35249ae–e35249ae.
10.
Planchard, David, Michael Boyer, Arunee Dechaphunkul, et al.. (2018). Osimertinib vs standard of care (SoC) EGFR-TKI as first-line therapy in patients (pts) with untreated EGFRm advanced NSCLC: FLAURA post-progression outcomes. Annals of Oncology. 29. ix150–ix150.
11.
Planchard, David, Michael Boyer, Jin Sun Lee, et al.. (2018). 128O Osimertinib vs standard of care (SoC) EGFR-TKI as first-line therapy in patients (pts) with untreated EGFRm advanced NSCLC: FLAURA post-progression outcomes. Journal of Thoracic Oncology. 13(4). S72–S73.
12.
Soria, J.C., Carlos Dias Maciel, Jürgen R. Fischer, et al.. (2017). SELECT-2: a phase II, double-blind, randomized, placebo-controlled study to assess the efficacy of selumetinib plus docetaxel as a second-line treatment of patients with advanced or metastatic non-small-cell lung cancer. Annals of Oncology. 28(12). 3028–3036.
13.
Vansteenkiste, Johan, Thanyanan Reungwetwattana, Kazuhiko Nakagawa, et al.. (2017). CNS response to osimertinib vs standard of care (SoC) EGFR-TKI as first-line therapy in patients (pts) with EGFR-TKI sensitising mutation (EGFRm)-positive advanced non-small cell lung cancer (NSCLC): Data from the FLAURA study. Annals of Oncology. 28. x189–x189.
14.
Vansteenkiste, Johan, Thanyanan Reungwetwattana, Ken Nakagawa, et al.. (2017). CNS response to osimertinib vs standard of care (SoC) EGFR-TKI as first-line therapy in patients (pts) with EGFR-TKI sensitising mutation (EGFRm)-positive advanced non-small cell lung cancer (NSCLC): Data from the FLAURA study. Annals of Oncology. 28. x196–x196.
15.
Robak, Tadeusz, Sebastian Grosicki, Krzysztof Warzocha, et al.. (2015). Ofatumumab (O) in combination with fludarabine (F) and cyclophosphamide (C) (OFC) vs. FC in patients with relapsed chronic lymphocytic leukaemia (CLL): results of the phase III study complement 2. Haematologica. 100.
16.
Tausch, Eugen, R. Schlenk, Peter Hillmen, et al.. (2014). SF3B1 mutations and outcome in CLL patients treated with chlorambucil (CHL) or ofatumumab-CHL (O plus CHL): results from the phase III study complement 1 (OMB110911). Haematologica. 99. 522–523.
17.
Hillmen, Peter, Tadeusz Robak, Ann Janssens, et al.. (2013). Ofatumumab + Chlorambucil Versus Chlorambucil Alone In Patients With Untreated Chronic Lymphocytic Leukemia (CLL): Results Of The Phase III Study Complement 1 (OMB110911). Blood. 122(21). 528–528.
18.
Deng, Jingti, Jonathan R. Lamb, Astrid McKeown, et al.. (2013). Identification of altered dipeptidyl-peptidase activities as potential biomarkers for unipolar depression. Journal of Affective Disorders. 151(2). 667–672.
19.
Domenici, Enrico, David Willé, Federica Tozzi, et al.. (2010). Plasma Protein Biomarkers for Depression and Schizophrenia by Multi Analyte Profiling of Case-Control Collections. PLoS ONE. 5(2). e9166–e9166.
20.
Kupfer, Bernd, Tobias Sing, Peter J. Schüffler, et al.. (2007). Fifteen years of Env C2V3C3 evolution in six individuals infected clonally with human immunodeficiency virus type 1. Journal of Medical Virology. 79(11). 1629–1639.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Motoshige Kudo Breakdown of academic impact, for papers by Claus G. Haase Breakdown of academic impact, for papers by Anna Arnal Estape Breakdown of academic impact, for papers by Sunil Mukhopadhyay Breakdown of academic impact, for papers by Ross Waite Breakdown of academic impact, for papers by Sean T. Glenn Breakdown of academic impact, for papers by Cheri Geist Breakdown of academic impact, for papers by Sanaa Nabha Breakdown of academic impact, for papers by Kelli B. Pointer Breakdown of academic impact, for papers by Elena Martínez‐Sáez